• Our News

PITTSBURGH–(BUSINESS WIRE)–ALung Technologies, Inc., the leading provider of low-flow extracorporeal carbon dioxide removal (ECCO2R) technologies for treating patients with acute respiratory failure, announced today the achievement of a major milestone in its U.S. based VENT-AVOID clinical trial and reports continued progress in its clinical trial programs. The independent Data and Safety Monitoring Board (DSMB) of the VENT-AVOID trial recommended continuation of the trial without modification following its first scheduled review of safety data from the initial 31 subjects enrolled.

“The attainment of this significant VENT-AVOID milestone is gratifying, and we look forward to the continuation of these pivotal trials, both of which hold the promise that the Hemolung RAS and ECCO2R therapy will provide a new tool in the treatment of acute respiratory failure”

Tweet this
COPD affects 30 million Americans1 and is the third leading cause of death in the United States behind cancer and heart disease.2 Acute exacerbations, defined as a sudden worsening of COPD symptoms, are a major cause of morbidity and mortality in COPD patients. The VENT-AVOID Trial is the world’s first pivotal study of ECCO2R in the AE-COPD population. The study aims to validate the safety and efficacy of the Hemolung Respiratory Assist System (RAS) for COPD patients experiencing acute exacerbations requiring ventilatory support. Nearly thirty hospitals have been brought online and are screening patients for ALung’s VENT-AVOID Trial of the Hemolung RAS.

In the United Kingdom, the REST Trial, a landmark pivotal study of the Hemolung RAS in patients with acute respiratory distress syndrome (ARDS), has enrolled greater than 360 patients. Significant progress continues to be made enrolling patients in this landmark pivotal study of the Hemolung RAS in patients with acute respiratory distress syndrome, and it is now the largest prospective clinical study of extracorporeal lung support ever conducted. ALung’s Hemolung RAS is the exclusive ECCO2R technology being used in the trial. The research is jointly led by Queen’s University and Belfast Health and Social Services Trust under the direction of investigators Professor Danny McAuley and Dr. James McNamee of the Centre for Experimental Medicine at Queen’s University Belfast.

“The attainment of this significant VENT-AVOID milestone is gratifying, and we look forward to the continuation of these pivotal trials, both of which hold the promise that the Hemolung RAS and ECCO2R therapy will provide a new tool in the treatment of acute respiratory failure,” stated Peter DeComo, Chairman and CEO of ALung.

The Hemolung RAS has European marketing clearance (CE Mark) and is the world’s only fully integrated Respiratory Dialysis® system. ALung is the only company pursuing two major pivotal trials to validate the safety and efficacy of extracorporeal carbon dioxide removal therapy.

About ALung Technologies

ALung Technologies, Inc. is a privately-held Pittsburgh-based developer and manufacturer of innovative lung assist devices. Founded in 1997 as a spin-out of the University of Pittsburgh, ALung has developed the Hemolung RAS as a dialysis-like alternative or supplement to mechanical ventilation. ALung is backed by Philips, UPMC Enterprises, Abiomed, The Accelerator Fund, Allos Ventures, Birchmere Ventures, Blue Tree Ventures, Eagle Ventures, Riverfront Ventures, West Capital Advisors, and other individual investors.

For more information about ALung and the Hemolung RAS, visit www.alung.com.

For more information on the VENT-AVOID trial, and a list of enrolling sites, please visit clinicaltrials.gov.

For more information about the REST Trial, please visit UK National Institute for Health Research (NIHR) – REST Trial Project Website.

CAUTION: The Hemolung RAS is an Investigational Device and limited by United States law to investigational use.

This press release may contain forward-looking statements, which, if not based on historical facts, involve current assumptions and forecasts as well as risks and uncertainties. Our actual results may differ materially from the results or events stated in the forward-looking statements, including, but not limited to, certain events not within the Company’s control. Events that could cause results to differ include failure to meet ongoing developmental and manufacturing timelines, changing GMP requirements, the need for additional capital requirements, risks associated with regulatory approval processes, adverse changes to reimbursement for the Company’s products/services, and delays with respect to market acceptance of new products/services and technologies. Other risks may be detailed from time to time, but the Company does not attempt to revise or update its forward-looking statements even if future experience or changes make it evident that any projected events or results expressed or implied therein will not be realized.

1. https://www.copdfoundation.org/What-is-COPD/COPD-Facts/Statistics.aspx
2. http://www.lung.org/assets/documents/research/copd-trend-report.pdf

ALung Technologies, Inc.
Peter M. DeComo
Chairman and CEO
+1-412-697-3370 ext. 207


That famous logo of a mallet-wielding rider at full gallop now bears a bag for recycling, so to speak.

A Pittsburgh company that converts discarded plastic bottles into fabric has a new customer — the Ralph Lauren Corp. (NYSE:RL).

Thread International PBC Inc. is no stranger to working with major brands, supplying Timberland, Reebock and Aerie. Now its fabric is being used by Ralph Lauren for the retailer’s latest twist on its iconic polo shirt.

Last week, the Earth Polo, made from fabric created from recycled plastic bottles, debuted at $89.50 per shirt, according to www.RalphLauren.com. Each shirt is made from 12 plastic bottles and Ralph Lauren has pledged to recycle170 million plastic bottles by 2025.

Ian Rosenberger, Thread founder and CEO, declined to disclose financial terms.

“They’re kind of America’s brand,” Rosenberger said of Ralph Lauren. “We’ve been chatting for a year or so. We have a well-established pipeline of companies we want to work with.”

Rosenberger launched Thread in the wake of the 2010 earthquake that devastated Haiti, creating an initiative to pay people for retrieving plastic bottles which are in turn converted to fabric for clothing, footwear and accessories. Sourcing was subsequently expanded to Honduras and Taiwan.

Thread isn’t limited to fabric. Since 2016, Hewlett-Packard Co. has used its recycled plastic to manufacture inkjet cartridges.

Last year, Thread debuted its own first product, a bag it dubbed “the Better Backpack.” Rosenberger plans to extend Thread’s line while continuing to supply materials to other companies.


Tim Armstrong, the former CEO and chairman of AOL and a former Google executive, has invested $2 million in Pittsburgh-based Niche.

By   – Senior Reporter, Pittsburgh Business Times

A big name in tech circles is providing his expertise plus a $2 million investment to a Pittsburgh company.

Niche, developer of a recruitment platform that helped more than 60 million people chose their school or neighborhood last year, on Thursday said that Tim Armstrong invested $2 million in its $8.6 million Series B financing round and has become an advisor to the company.

Armstrong, now CEO and founder of the newly launched dtx company, was formerly CEO of AOL/Yahoo/Oath and president of the Americas at Google.

“As Millennials move into parenthood and Gen Z goes off to college, the decision-making process around how and why we choose schools, neighborhoods and workplaces is dramatically changing,” Armstrong said in a prepared statement. “Niche’s platform is ahead of this shift, empowering consumers with greater insight and helping schools thrive in an environment of increased competition.”

Other investors in Niche’s funding round are Allen & Co. and Grit Capital Partners, both based in New York.

Niche’s founder and CEO Luke Skurman launched the company with colleagues at Carnegie Mellon University in 2002. Originally called College Prowler, it rebranded as Niche in fall 2013 and expanded its reach. Skurman was not immediately available for comment.

Niche analyzes dozens of data sets and hundreds of millions of ratings and reviews to produce comprehensive rankings, report cards and profiles for every K-12 school, college, neighborhood and major employer in America. Sales for its subscription recruiting platform grew 200 percent in 2018, Niche said, and it now helps more than 800 client schools find best-fit students.


A LifeX startup company is taking aim at antibiotic-resistant infections in artificial joints, which have few good treatment options for doctors and consequences for the patient that can be painful and costly.

Oakland-based Peptilogics Inc. has received approval from Australia’s Therapeutics Goods Administration to begin the first in-human study of its PLG0206 product, which targets prosthetic joint infections. The clinical trial received ethics approval from the Bellberry Human Research Ethics Committee.

“Everyone knows someone who’s had one, but I wasn’t aware how devastating the infections could be,” said Peptilogics founder and CEO Jonathan Steckbeck, 42. “There are only a few effective therapies, and none are terribly effective.”

Peptilogics is an early clinical stage biotechnology company and among 10 startups in the LifeX portfolio of 16 companies that are seeking to develop therapeutic agents. LifeX is a nonprofit South Side small business accelerator funded by the University of Pittsburgh.


LifeX Ventures founder and CEO Dietrich Stephan of Squirrel Hill leads a meeting to discuss the progress of several health and wellness companies Wednesday Nov. 28, 2018, at LifeX on the Southside. This University of Pittsburgh-funded nonprofit, aids research groups that hope to produce new medical therapies that aid patients. (Jessie Wardarski/Post-Gazette)
LifeX startups face especially long odds in attacking some of medicine’s biggest challenges

Six-year-old Peptilogics, which also has an office in San Jose, Calif., does not yet have revenue. The startup has raised $6.8 million from investors, including Peter Thiel, founder of the Founders Fund of San Francisco; Pine-based BlueTree Venture Fund; and serial entrepreneur Stefan Roever, who lives in Bonn, Germany.

The death of his father-in-law in 2004 from a bacterial infection spurred Mr. Steckbeck’s interest in antibiotic-resistant microbes, he said. The company has two full-time employees and 12 contractors.

Taking risk is necessary for growth. This series profiles the region’s entrepreneurs, policymakers, scientists and others who have embraced challenges and incorporated new ideas – sometimes the kind that seem a little crazy – into their plans.
Infection of an artificial hip or knee joint can arise any time after surgery, a condition Mr. Steckbeck called “heartbreaking,” and affects 20,000 people annually. The number is expected to rise as joint replacement surgeries increase with an aging population.

More than 1.2 million hip and knee replacements were performed during the year ending in August, according to the American Academy of Orthopaedic Surgeons. Studies have shown that 1 percent to 2 percent of those operations will result in an infection on the biofilm that forms on the implant.

Physician Neel Shah, an infectious disease specialist at the University of Pittsburgh, said that when a new joint becomes infected, sometimes the only option is to remove the prosthesis, a procedure that has a success rate ranging between 80 percent and 90 percent. Treatment of an infection with the joint in place has a variable overall success rate, between 20 percent and 80 percent.

One choice for treating a joint without removal of the implant is opening the incision and flooding the new joint with an antibiotic solution, a practice that Mr. Steckbeck called a “powerwash.” The procedure often fails, he said, and the cost of treating prosthetic joint infections can reach $100,000.

In a recent experiment, Peptilogics created an infected biofilm on an artificial joint before saturating the implant with commonly used antibiotics, Mr. Steckbeck said. Not all of the bacteria were killed, even after 24 hours of exposure.

But with the Peptilogics product, which is being developed as an injectable drug, essentially all of the bacteria were dead within 30 minutes.

The first Food and Drug Administration-approved trial in humans is anticipated at the end of 2019, Mr. Steckbeck said. If all goes well, the drug could be commercialized for use in the U.S. within a few years, he said.

Expedia Group’s $21.5 million acquisition of Chicago-based ApartmentJet Inc. translates into a windfall for angel investors in Pittsburgh.

BlueTree Venture Fund and BlueTree Allied Angels will realize a 4.3 times return on its combined $450,000 investment in less than a year, said Catherine Mott, founder, CEO and managing partner of 15-year-old Wexford-based BlueTree Capital Group LLC.

“This is the quickest exit we have ever experienced,” Mott said.

The venture fund invested $150,000 in ApartmentJet last November and the angel group invested $300,000 in the young company in February, she said.

“On average, our previous profitable exits range with holding periods of four to six years,” Mott said. “The largest return historically for us is Wombat with a 12 times return.”

In February, Pittsburgh-based Wombat Security Technologies, a security awareness and training software firm, was acquired for $225 million by Proofpoint, a Silicon Valley cybersecurity company. BlueTree Allied Angels invested $266,500 in Wombat over a three-year period.

BlueTree Venture Fund has $10 million and BlueTree Allied Angels has $40 million under management.

ApartmentJet is a web-based platform to help multifamily property owners and management companies take advantage of the growing market for short-term rentals.

“Demand for short-term rentals in U.S. urban destinations has been growing impressively over the past several years,” Mark Okerstrom, Expedia (Nasdaq:EXPE) president and CEO, said in a prepared statement. “In order to be able to deliver our customers what they are asking for while at the same time promoting responsible renting, Expedia Group is committed to delivering solutions that give urban building owners, managers and communities control and transparency over short-term rentals.”



Thread International moves to Homewood, employs locals and launches its own line of recycled backpacks




Search for

Contact Us

BlueTree Venture Fund
P.O. Box 1323
Wexford, PA 15090